AP828A - Process and crystal forms of 2-methyl-thieno-benzodiazepine. - Google Patents

Process and crystal forms of 2-methyl-thieno-benzodiazepine. Download PDF

Info

Publication number
AP828A
AP828A APAP/P/1997/001065A AP9701065A AP828A AP 828 A AP828 A AP 828A AP 9701065 A AP9701065 A AP 9701065A AP 828 A AP828 A AP 828A
Authority
AP
ARIPO
Prior art keywords
olanzapine
polymorph
active ingredient
methyl
ray powder
Prior art date
Application number
APAP/P/1997/001065A
Other languages
English (en)
Other versions
AP9701065A0 (en
Inventor
Charles Arthur Bunnell
Barry Arnold Hendriksen
Samuel Dean Larsen
Original Assignee
Lilly Co Eli
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP828(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Lilly Industries Ltd filed Critical Lilly Co Eli
Publication of AP9701065A0 publication Critical patent/AP9701065A0/xx
Application granted granted Critical
Publication of AP828A publication Critical patent/AP828A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
APAP/P/1997/001065A 1995-03-24 1996-03-22 Process and crystal forms of 2-methyl-thieno-benzodiazepine. AP828A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24
PCT/US1996/003917 WO1996030375A1 (en) 1995-03-24 1996-03-22 Process and crystal forms of 2-methyl-thieno-benzodiazepine

Publications (2)

Publication Number Publication Date
AP9701065A0 AP9701065A0 (en) 1997-10-31
AP828A true AP828A (en) 2000-04-28

Family

ID=23621056

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001065A AP828A (en) 1995-03-24 1996-03-22 Process and crystal forms of 2-methyl-thieno-benzodiazepine.

Country Status (48)

Country Link
US (1) US5736541A (de)
EP (3) EP1095941B1 (de)
JP (1) JPH11502535A (de)
KR (1) KR100399688B1 (de)
CN (1) CN1065536C (de)
AP (1) AP828A (de)
AR (2) AR002719A1 (de)
AT (4) ATE251627T1 (de)
AU (1) AU706471B2 (de)
BG (1) BG62619B1 (de)
BR (1) BR9607790A (de)
CA (1) CA2214005C (de)
CH (1) CH690579A5 (de)
CO (1) CO4650278A1 (de)
CZ (1) CZ292688B6 (de)
DE (4) DE69630324T2 (de)
DK (4) DK1095941T3 (de)
EA (1) EA000149B1 (de)
EE (1) EE03489B1 (de)
EG (1) EG23659A (de)
ES (3) ES2208220T3 (de)
FI (1) FI973750A7 (de)
GB (1) GB2313835B (de)
HU (1) HU224989B1 (de)
IL (1) IL117610A (de)
IS (1) IS1896B (de)
LT (1) LT4349B (de)
LU (1) LU90096B1 (de)
LV (1) LV12018B (de)
MY (1) MY114701A (de)
NO (1) NO314663B1 (de)
NZ (1) NZ306110A (de)
OA (1) OA10510A (de)
PA (1) PA8353701A1 (de)
PE (1) PE44897A1 (de)
PL (1) PL183723B1 (de)
PT (3) PT1095941E (de)
RO (1) RO118872B1 (de)
SE (1) SE9703205L (de)
SI (4) SI0733635T1 (de)
SK (1) SK284143B6 (de)
SV (1) SV1996000031A (de)
TR (1) TR199701017T1 (de)
TW (2) TW513432B (de)
UA (1) UA44765C2 (de)
WO (1) WO1996030375A1 (de)
YU (1) YU49478B (de)
ZA (2) ZA962344B (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
AU7013196A (en) * 1995-09-29 1997-04-17 Eli Lilly And Company Method for treating a tic disorder
CZ290198A3 (cs) * 1996-03-11 1999-09-15 Eli Lilly And Company Farmaceutický prostředek pro ošetřování nespavosti
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
CA2250155A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Anesthetic method
US5929070A (en) * 1996-03-25 1999-07-27 Eli Lilly And Company Method for treating migraine pain with olanzapine
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
AU721338B2 (en) * 1996-03-25 2000-06-29 Eli Lilly And Company Method for treating pain
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
NZ334346A (en) * 1996-09-23 2000-05-26 Lilly Co Eli Olanzapine dihydrate D comprising 2-methyl-4-(4-methyl-1-piperazinyl)-1OH-thieno[2,3-b][1,5]benzodiazepine and a formulation for use in treating central nervous system disorders
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
DK1155696T3 (da) * 1997-04-15 2004-07-12 Lilly Co Eli Anvendelse af olanzapin til fremstillingen af et medikament til neurobeskyttelse
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
WO1998046596A1 (en) * 1997-04-15 1998-10-22 Eli Lilly And Company Method for providing neuro-protective effects
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
AU759751B2 (en) * 1998-09-30 2003-05-01 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
EP1246827B1 (de) * 1999-12-28 2005-04-13 Cipla Limited Neue polymorphe formen von olanzapin
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2002018390A1 (en) * 2000-08-31 2002-03-07 Dr. Reddy's Laboratories Ltd. Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
WO2002019998A2 (en) * 2000-09-08 2002-03-14 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
EP1440074A1 (de) * 2001-10-29 2004-07-28 Dr. Reddy's Laboratories Ltd. Olanzapin dihydrat-ii, verfahren zu ihrer herstellung und ihre anwendung
EP1470130A2 (de) * 2001-12-24 2004-10-27 Sun Pharmaceuticals Industries Ltd. Kristalline form i von 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno 2,3-b 1,5 benzodiazepin
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
JP4906233B2 (ja) * 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも１種の有効薬剤成分を含有する多構成要素固相
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
WO2003101997A1 (en) 2002-05-31 2003-12-11 Geneva Pharmaceuticals, Inc. Process of preparation of olanzapine form i
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
WO2004058773A1 (en) * 2002-12-24 2004-07-15 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
ATE352305T1 (de) * 2003-03-12 2007-02-15 Teva Pharma Stabile pharmazeutische zusammensetzungen mit desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
US20070148218A1 (en) * 2003-11-18 2007-06-28 Gordon Ryan D Olanzapine containing transdermal drug delivery compositions
PT1611139E (pt) * 2003-12-22 2008-07-17 Teva Pharma Métodos de preparação de olanzapina
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
EP1709053B1 (de) 2004-01-27 2011-04-06 Synthon B.V. Stabile salze von olanzapin
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
WO2006027800A1 (en) * 2004-09-06 2006-03-16 Shasun Chemicals And Drugs Limited A novel process for preparation of a pharmaceutically pure polymorphic form 1 of olanzapine
EP1827374B1 (de) * 2004-11-16 2014-11-05 Alkermes Pharma Ireland Limited Injizierbare olanzapin-formulierungen in nanoteilchenform
DK1838716T3 (da) 2005-01-05 2011-07-25 Lilly Co Eli Olanzapinpamota-dihydrat
CZ200563A3 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
KR20070113277A (ko) * 2005-03-21 2007-11-28 닥터 레디스 레보러터리즈 리미티드 올란자핀의 결정 형태 ｉ의 제조방법
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (de) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Olanzapinreinigungsverfahren
HUE041981T2 (hu) 2010-08-23 2019-06-28 Alkermes Pharma Ireland Ltd Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
JP6374387B2 (ja) 2012-08-21 2018-08-15 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンハプテンへの抗体及びその使用
CN104755093B (zh) * 2012-08-21 2018-11-16 詹森药业有限公司 奥氮平半抗原的抗体及其用途
US9494608B2 (en) 2012-08-21 2016-11-15 Janssen Pharmaceutica Nv Antibodies to olanzapine and use thereof
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
EP4465968A1 (de) 2022-01-20 2024-11-27 Teva Pharmaceuticals International GmbH Olanzapin, zusammensetzungen davon und verfahren zur verwendung davon
AU2024208071A1 (en) 2023-01-10 2025-06-12 Medincell Sa Olanzapine compositions and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
DK0582368T3 (da) * 1992-05-29 2001-02-05 Lilly Co Eli Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
EE9700232A (et) 1998-04-15
DE69630324D1 (de) 2003-11-13
NO974365D0 (no) 1997-09-22
WO1996030375A1 (en) 1996-10-03
LV12018A (lv) 1998-04-20
SE9703205D0 (sv) 1997-09-05
SI1445259T1 (sl) 2006-10-31
CO4650278A1 (es) 1998-09-03
IS4564A (is) 1997-09-22
DK108997A (da) 1997-11-12
DK0733635T3 (da) 2001-10-08
EP0733635B1 (de) 2001-08-16
IL117610A (en) 2001-08-26
PT1095941E (pt) 2004-02-27
ES2208220T3 (es) 2004-06-16
DE69636313T2 (de) 2007-05-31
KR100399688B1 (ko) 2004-02-18
LU90096B1 (fr) 1997-07-22
BG101900A (en) 1999-03-31
CN1065536C (zh) 2001-05-09
SI9620040B (sl) 2002-02-28
CZ300097A3 (en) 1997-12-17
ES2266719T3 (es) 2007-03-01
ATE251627T1 (de) 2003-10-15
GB2313835A (en) 1997-12-10
DE69630324T2 (de) 2004-07-29
BR9607790A (pt) 1998-07-07
HU224989B1 (en) 2006-05-29
HUP9802824A2 (hu) 1999-06-28
KR19980703188A (ko) 1998-10-15
US5736541A (en) 1998-04-07
MX9707183A (es) 1997-11-29
EA000149B1 (ru) 1998-10-29
TW513432B (en) 2002-12-11
AR002719A1 (es) 1998-04-29
EE03489B1 (et) 2001-08-15
EG23659A (en) 2007-03-26
CZ292688B6 (cs) 2003-11-12
DK1445259T3 (da) 2006-10-16
UA44765C2 (uk) 2002-03-15
DE69636313D1 (de) 2006-08-10
EP0733635A1 (de) 1996-09-25
AU706471B2 (en) 1999-06-17
DE19681286T1 (de) 1998-04-02
SK284143B6 (sk) 2004-10-05
TR199701017T1 (xx) 1998-01-21
YU17796A (sh) 1999-03-04
CH690579A5 (de) 2000-10-31
EP1095941A1 (de) 2001-05-02
CA2214005A1 (en) 1996-10-03
FI973750L (fi) 1997-09-22
FI973750A0 (fi) 1997-09-22
SI9620040A (sl) 1998-06-30
EP1445259A1 (de) 2004-08-11
ZA962342B (en) 1997-09-22
NZ306110A (en) 1998-09-24
GB2313835B (en) 1998-09-16
NO314663B1 (no) 2003-04-28
ZA962344B (en) 1997-09-22
LV12018B (en) 1998-09-20
LT4349B (lt) 1998-05-25
MY114701A (en) 2002-12-31
RO118872B1 (ro) 2003-12-30
SV1996000031A (es) 1998-03-27
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
DE69614426D1 (de) 2001-09-20
YU49478B (sh) 2006-05-25
LT97148A (lt) 1998-01-26
DE69614426T2 (de) 2002-05-23
SE9703205L (sv) 1997-09-05
AU5427996A (en) 1996-10-16
PT733635E (pt) 2001-12-28
ATE204280T1 (de) 2001-09-15
ATE331719T1 (de) 2006-07-15
CA2214005C (en) 2001-07-03
IL117610A0 (en) 1996-07-23
PE44897A1 (es) 1997-10-22
EP1095941B1 (de) 2003-10-08
SI0733635T1 (en) 2002-06-30
DK1095941T3 (da) 2004-02-16
FI973750A7 (fi) 1997-09-22
CN1179160A (zh) 1998-04-15
OA10510A (en) 2002-04-24
PL322501A1 (en) 1998-02-02
ATA902196A (de) 2000-01-15
HK1013988A1 (en) 1999-09-17
BG62619B1 (bg) 2000-03-31
JPH11502535A (ja) 1999-03-02
IS1896B (is) 2003-10-20
ES2159346T3 (es) 2001-10-01
EP1445259B1 (de) 2006-06-28
HUP9802824A3 (en) 2000-01-28
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
EA199700262A1 (ru) 1998-02-26
GB9719819D0 (en) 1997-11-19
TW442488B (en) 2001-06-23
NO974365L (no) 1997-09-22
AT406771B (de) 2000-08-25
SI1095941T1 (en) 2003-12-31
SK121897A3 (en) 1998-03-04
PL183723B1 (pl) 2002-07-31

Similar Documents

Publication Publication Date Title
AP828A (en) Process and crystal forms of 2-methyl-thieno-benzodiazepine.
AU720366B2 (en) Olanzapine dihydrate D
WO1996038151A1 (en) Method for treating cognitive dysfunction
HK1013988B (en) Crystal forms of a thieno(2,3-b)(1,5) benzodiazepine derivative and process for their preparation
MXPA97007183A (en) A process and glass forms of 2-methyl-tieno-benzodiazep
US6506746B2 (en) Method for treating cognitive dysfunction
HK1009809B (en) Olanzapine dihydrate d